The potent synthetic TLR7 agonist imiquimod, approved for the treatment of basal cell carcinoma (200), was shown to increase the infiltration of activated pDCs into melanoma lesions and its combination with monobenzone led to metastases regression in phase II clinical trial in late-stage melanoma patients (201). The gene discussed is TLR7; the disease is melanoma.